| Marc-Eric Halatsch | OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs |
| Sookyung Lee | A potential treatment option for elderly non-Hodgkin lymphoma patients with multiple comorbidities: Two case reports and literature review |
| György Losonczy | Gefitinib treatment in lung cancer — rebiopsy retreatment remission |
| Stefanie Klein | Caffeic Acid, Quercetin and 5-Fluorocytidine-Functionalized Au-Fe3O4 Nanoheterodimers for X-ray-Triggered Drug Delivery in Breast Tumor Spheroids |
| Michael Tovey | Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma |
| Chin-Tarng Lin | A multifunctional peptide for targeted imaging and chemotherapy for nasopharyngeal and breast cancers |
| Laura Soucek | A clinically viable anti-MYC protein therapeutic for cancer treatment |
| Sorrentino Rosalinda | Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness |
| Huget Desiron | Bridging Health Care and the Workplace: Formulation of a Return-to-Work Intervention for Breast Cancer Patients Using an Intervention Mapping Approach |
| Angela Ruban | Blood glutamate scavengers increase pro‚Äëapoptotic signaling and reduce metastatic melanoma growth in‚Äëvivo |
| Ronald Korn | New radiologic approaches for evaluating solid tumors beyond RECIST |
| Robert Clarke | Endocrine Resistance in Breast Cancer – A Cancer Systems Biology Perspective |
| Hye Seon Kang | Smoking and lung cancer treatment |
| Deborah J. Bowen | Improving CRC outcomes through intervention at all risk levels |
| Joshua D Campbell | Transdermal delivery using Microstructures |
| Christopher Miller | Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining: tissue processing methodology to optimize pathologic staging an |
| Shelly R Peyton | Tumor cell-organized fibronectin maintenance of a dormant breast cancer population |
| Atena Zahedi | Epithelial-to-mesenchymal transition of A549 lung cancer cells exposed to electronic cigarettes |
| Veda Giri | Genetic Evaluation for Inherited Prostate Cancer |
| Frank Gansauge | Effectivity of long antigen exposition dendritic cell therapy (LANEXDC®) in the palliative treatment of pancreatic cancer |
| Konstantin Zioutas | Planetary relationships in medicine |
| Bryan Allen | Radioresistance in Glioblastoma and the Development of Radiosensitizers |
| Darren Patten | New approaches in the management of male breast cancer |
| Xiaofeng Shi | Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient |
| Cheng-Har Yip | The Will Rogers phenomenon in the staging of breast cancer – Does it matter |
| Luciana Pantaleão | Study of 448 cases of melanoma in situ in two hospitals in Rio de Janeiro |
| Laura Poliseno | Unraveling the biology of BRAFV600E isoforms in melanoma |
| Sergio Augusto Lopes de Souza | Development of 131 I-ixolaris as a theranostic agent: metastatic melanoma preclinical studies |
| David Frank | Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer |
| Masakazu Kamata | anoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model |
| PANGALIS GERASSIMOS | Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma |
| Hinanit Koltai | Specific Compositions of Cannabis sativa Compounds Have Cytotoxic Activity and Inhibit Motility and Colony Formation of Human Glioblastoma Cells In Vitro |
| Gaël Roué | Management of Drug Resistance in Mantle Cell Lymphoma |
| Gaia Favero | Melatonin’s Antineoplastic Potential Against Glioblastoma |
| Renhua Li | A Gene Regulatory Program in Human Breast Cancer |
| Jason Chesney | Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors |
| Diego Hernandez | La mortalidad por melanoma en M√(c)xico aumenta |
| Eric Gyan | Tissue resident Immune cells in African Breast Cancer Patients |
| Vinicius Cavalheri | Exercise as medicine across the lung cancer continuum |
| Ronald Myers | A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients |
| Yasunari Kawabata | Superior mesenteric artery-first approach in radical antegrade modular pancreatosplenectomy for borderline resectable pancreatic cancer: a technique to obtain negative tangential margins |
| Mary-Ann Dalzell | Time course of upper limb function and return-to-work post-radiotherapy in young adults with breast cancer: a pilot randomized control trial on effects of targeted exercise program |
| Xuehong Zhang | The Etiology, Epidemiology, Prevention of Liver Cancer |
| Xin Yu | Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer |
| Bojana Obradovic | Development of 3D cancer cell culture models for anti-tumor drug testing |
| Laura Patrussi | Abnormalities in chemokine receptor recycling in chronic lymphocytic leukemia |
| Frederick Bebe | Metastatic melanoma in Florida, 1996-2010: Racial, etastatic melanoma in Florida, 1996-2010: Racial, demographic, occupational and tumor characteristics, c, occupational and tumor characteristics, and burden of met√°stasis nd burden of met√°stasis |
| Dorothy Makanjuola | Defining radiologic complete response using a correlation of presurgical ultrasound and mammographic localization findings with pathological complete response following neoadjuvant chemotherapy in breast cancer |
| Sollier Elodie | Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer |
| Sabine Brandt | Canine oral primary melanoma cells exhibit shift to mesenchymal phenotype and phagocytic behaviour |
| Yuki Yoshimatsu | Establishment and characterization novel patient-derived extraskeletal cell line NCC-ESOS1-C1 |
